Affiliation:
1. Fudan University Pudong Medical Center
2. Fudan University Shanghai Cancer Center
Abstract
Abstract
Aim
Cholangiocarcinoma (CCA) is the most common malignant tumor of the bile ducts. Due to its anatomical location, growth pattern, and lack of clear diagnostic criteria, it presents diagnostic challenges. Exploring its occurrence and development to find early markers and treatment targets is of great significance.
Methods
To determine whether Mucin 3A (MUC3A) can regulate the occurrence and development of cholangiocarcinoma cells and its mechanism, we constructed stable transfections of KONC (transfection negative control group) and MUC3A-KO1 and KO2 (transfection MUC3A knockout vectors) lentivirus in RBE cell lines. We investigated the effect of MUC3A on the proliferative capacity of cholangiocarcinoma cells using the CCK-8 assay and colony formation assay. The regulatory effect of MUC3A on the cell cycle of cholangiocarcinoma cells was examined using flow cytometry. The impact of MUC3A on the invasion and migration of cholangiocarcinoma cells was observed through scratch and Transwell assays. Additionally, the mechanism by which MUC3A regulates proliferation and metastasis of cholangiocarcinoma was explored using Western blot.
Results
MUC3A promotes the proliferation of cholangiocarcinoma cells by regulating the cell cycle. Additionally, MUC3A enhances the invasion and migration of cholangiocarcinoma cells by regulating the epithelial-mesenchymal transition(EMT). Furthermore, MUC3A regulates the proliferation and metastasis of cholangiocarcinoma cells through the ERK signaling pathway.
Conclusions
This study demonstrates that MUC3A regulates the proliferation and metastasis of cholangiocarcinoma cells through the ERK signaling pathway.
Publisher
Research Square Platform LLC
Reference33 articles.
1. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians;Moris D;Cancer J Clin,2023
2. Banales JM et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature reviews. Gastroenterology & hepatology 17, 557–588 (2020).
3. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer Stat 2023 CA: cancer J Clin. 2023;73:17–48.
4. Systemic therapies for intrahepatic cholangiocarcinoma;Kelley RK;J Hepatol,2020
5. Current and emerging therapies for advanced biliary tract cancers;Kam AE;lancet Gastroenterol Hepatol,2021